MyMycoLab Review: Mycotoxin Blood Serum Antibody Test

Figure 1. MyMycoLab analyzes a blood serum sample for antibodies to mold toxins, an immune-response approach rather than a direct toxin measurement.

MyMycoLab describes its product as an indirect blood-serum test that reports IgG and IgE antibody measurements for 14 listed mycotoxins, producing 28 results. These descriptions come from the company. The panel samples blood, not a building, and it cannot establish illness, exposure, causation, a source location, treatment need, clearance, or safe occupancy.

Figure 2. MyMycoLab says a phlebotomist collects blood and the serum is returned to its laboratory.

• MyMycoLab states that patients can order without a physician referral.
• The company says a phlebotomist must collect the blood sample using the kit instructions.
• The serum is packaged and returned under the company directions.
• MyMycoLab says it reports IgG and IgE antibody measurements for each of 14 listed mycotoxins.
• The company lists about 14 business days after laboratory receipt and says a written interpretation and optional advisor consultation are included.

These process details do not independently validate the panel or make its result diagnostic.

MyMycoLab lists 14 mycotoxins in two antibody classes, IgG and IgE, for 28 reported measurements. The company says its current panel includes compounds such as Fumonisin B1 and Zearalenone. Panel contents can change, so these are time-sensitive company product facts.

What IgG and IgE are meant to signal

MyMycoLab publishes its own descriptions of IgG and IgE results. Those descriptions are company claims, not standardized cross-laboratory reference ranges. CDC and FDA do not recognize mycotoxin body testing as a validated way to diagnose mold-related illness. A result cannot establish exposure, causation, illness, or a treatment decision.

MyMycoLab lists the 28-measurement panel at $380. The company says that price covers the kit and laboratory analysis and includes a written interpretation and optional consultation. Pricing and terms can change.

• MyMycoLab says a phlebotomy fee, if charged, is separate.
• The company states that no physician referral is required for an order.
• MyMycoLab states that it does not bill insurance.
• The company says international return shipping is not included.

Price, direct availability, and included services do not establish clinical validity. This panel cannot answer whether mold is present in a building or whether a space is safe.

Figure 3. MyMycoLab describes an antibody measurement. That description does not establish clinical validity.

What the company reports

MyMycoLab calls its laboratory and method certified and validated, claims more than two decades of work behind the method, and says each report includes a written interpretation and optional consultation. The company identifies Dr. Andrew Campbell, MD, as its medical advisor. These are company and affiliation facts, not independent evidence that the panel predicts disease or supports a health or occupancy decision.

What has not been established

CDC and FDA do not recognize mycotoxin body testing as a validated way to diagnose mold-related illness. Agreed cross-laboratory reference ranges for this serum-antibody panel have not been established, and the approach is primarily associated with one laboratory. MyMycoLab's claim that its method is more accurate than urine testing is a company claim, not an independent clinical-validation standard. A result cannot diagnose illness, prove exposure or causation, identify a building source, choose treatment, or establish clearance or safe occupancy.

Blood versus urine

Urine panels report compounds in urine, while MyMycoLab reports antibody measurements from serum. Neither sample type is recognized by CDC or FDA as a validated diagnosis of mold-related illness, and neither can establish a building source or safe occupancy.

• The product uses blood serum and reports IgG and IgE measurements.
• MyMycoLab lists 14 mycotoxins and 28 total reported measurements.
• The company identifies a medical advisor and says a written interpretation and optional consultation are included.
• MyMycoLab states that no physician referral is required to order.
• The company lists several possible phlebotomy settings and about 14 business days after laboratory receipt.

None of these facts establishes clinical validity, diagnosis, causation, source, treatment need, clearance, or safe occupancy.

• The panel measures blood-serum antibodies, not conditions in a building.
• CDC and FDA do not recognize mycotoxin body testing as a validated diagnosis.
• Agreed cross-laboratory reference ranges have not been established.
• The methodology is primarily associated with one laboratory, limiting independent comparison.
• A phlebotomy appointment and separate fee may be required.
• The listed price is $380, the company says it does not bill insurance, and other fees may apply.
• A result cannot support diagnosis, causation, source, treatment, remediation, clearance, or occupancy decisions.

This panel is not a suitable basis for a diagnosis, exposure or causal conclusion, treatment decision, remediation scope, clearance, or occupancy decision. It cannot establish whether mold is present in a building or where a moisture source is located. Building questions require a qualified building investigation, and health concerns require evaluation under established medical guidance rather than interpretation of this unvalidated panel.

Versus urine mycotoxin labs (RealTime, Mosaic)

Urine labs such as RealTime Laboratories and Mosaic Diagnostics report compounds measured in urine. MyMycoLab instead reports antibody measurements from serum. There is no independent clinical-validation standard that makes either approach diagnostic. All sample the body rather than a building, and none can establish causation, source, or safe occupancy.

Versus DIY mold test kits

A DIY mold testing kit samples material from a building, while MyMycoLab samples blood. Settling plates and other limited DIY samples cannot establish a complete source, remediation scope, clearance, or safe occupancy.

Versus environmental dust testing (ERMI)

An ERMI test applies a research index to mold-DNA measurements from settled dust. EPA does not recommend ERMI for routine consumer use. A serum panel and a dust index measure different samples, and neither establishes illness, causation, source location, clearance, or safe occupancy.

Versus a professional inspection

A qualified building professional can investigate building history, moisture, accessible materials, and a defined sampling question. A blood result cannot perform that work. See the limits described in our guide on how to test for mold.

MyMycoLab publishes ordering, phlebotomy, packaging, return, and timing instructions for its product. Follow only the current company directions for handling a purchased kit. This review does not recommend buying the panel or using a result to diagnose illness, prove exposure or causation, identify a building source, choose treatment, define remediation, or establish clearance or safe occupancy.

MyMycoLab publishes a defined sample type, analyte list, collection process, price, and reporting timeframe. Those product facts do not establish clinical validity. CDC and FDA do not recognize mycotoxin body testing as a validated diagnosis, and agreed cross-laboratory reference ranges for this panel have not been established. Do not use the result to diagnose illness, prove exposure or causation, identify a building source, choose treatment, define remediation, or establish clearance or safe occupancy.

A blood panel and a building investigation answer different questions. Mold Scanner AI guides visible-surface photo capture and provides AI-assisted visual screening with variable processing time. It cannot locate hidden growth, trace a source, choose sampling sites, or determine whether a health test is warranted. Use a qualified inspector, laboratory, and clinician as appropriate. See how Mold Scanner AI works.